Ying Cheng

1.0k total citations · 1 hit paper
27 papers, 726 citations indexed

About

Ying Cheng is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ying Cheng has authored 27 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ying Cheng's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Diabetes and associated disorders (6 papers). Ying Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Diabetes and associated disorders (6 papers). Ying Cheng collaborates with scholars based in China, Hong Kong and United States. Ying Cheng's co-authors include Hongming Pan, Dawn M. Carlson, Jiang Qian, Ferry A.L.M. Eskens, Shukui Qin, Ik Joo Chung, Vera Gorbunova, Yoon‐Koo Kang, Pei‐Jer Chen and Justin L. Ricker and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ying Cheng

23 papers receiving 713 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

2014 465 citations Călin Cainap, Shukui Qin et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ying Cheng

Since Specialization

Citations

This map shows the geographic impact of Ying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Cheng more than expected).

Fields of papers citing papers by Ying Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Cheng. The network helps show where Ying Cheng may publish in the future.

Co-authorship network of co-authors of Ying Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Cheng. A scholar is included among the top collaborators of Ying Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Cheng. Ying Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LETM-domain containing 1 (LETMD1) protects against obesity via enhancing UCP1-independent energy expenditure in human beige adipocytes 2025 ·Theranostics ·(unknown), Ying Cheng, Qing Liu, Qiaoyun Long, (unknown), (unknown), Kerry M. Loomes, Xuefei Gao, Bin Lin, Xingguo Liu, Donghai Wu, Xiaoyan Hui	1
2	12P: Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial 2025 ·Journal of Thoracic Oncology ·Chengzhi Zhou, (unknown), Junru Chen, Xingxiang Xu, Ying Cheng, Gang Chen, Yueyin Pan, (unknown), Qi Wang, Yunchao Huang, Wu Yao, Rui Wang, Xiang Li, (unknown), Ying Zhang, Shengshou Hu, (unknown), (unknown), Zhoufeng Wang, (unknown)	0
3	Adipocyte-derived lactate is a signalling metabolite that potentiates adipose macrophage inflammation via targeting PHD2 2022 ·Nature Communications ·Tianshi Feng, Xuemei Zhao, Ping Gu, Wah Yang, Cunchuan Wang, (unknown), Qiaoyun Long, Qing Liu, Ying Cheng, Jin Li, (unknown), Donghai Wu, (unknown), Yong Xu, Dewei Ye, Shuang Hua, Kerry M. Loomes, Aimin Xu, Xiaoyan Hui	104
4	[Two-dimensional equivalent mechanical modeling and finite element analysis of normal female pelvic floor system]. 2022 ·PubMed ·(unknown), Ting Yao, (unknown), (unknown), (unknown), Zhenhua Gao, (unknown), Yin Mo, (unknown), Ying Cheng, (unknown), Jihong Shen	2
5	Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial 2021 ·The Journal of Clinical Endocrinology & Metabolism ·Lin Yang, Huiying Liang, Xinyuan Liu, Xia Wang, Ying Cheng, Yunjuan Zhao, (unknown), Gan Huang, Xiangbing Wang, Zhiguang Zhou	15
6	1370TiP Befotertinib versus icotinib as first-line treatment in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer: A multicenter, randomized, open-label, controlled phase III study 2021 ·Annals of Oncology ·(unknown), (unknown), (unknown), Liqing Wu, Ying Cheng, Yun Fan, Jian Fang, (unknown), (unknown), Dongqing Lv, Longying Jiang, Ruilin Wu, Xin Jin, (unknown), (unknown), (unknown), Dennis Huang, (unknown), Wei Guo, Liren Ding	2
7	Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib 2020 ·Journal of Thoracic Disease ·Jingjing Liu, Shuang Li, Shuang Zhang, Changliang Yang, Liang Zhang, Bin Zhang, Ying Cheng, Changli Wang	10
8	Diagnostic value of combined islet antigen‐reactive T cells and autoantibodies assays for type 1 diabetes mellitus 2020 ·Journal of Diabetes Investigation ·(unknown), Huiying Liang, Ying Cheng, (unknown), Gan Huang, Zhiguang Zhou, Lin Yang	7
9	Pathophysiological characteristics in patients with latent autoimmune diabetes in adults using clamp tests: evidence of a continuous disease spectrum of diabetes 2019 ·Acta Diabetologica ·Lin Yang, Xinyuan Liu, Huiying Liang, Ying Cheng, Gan Huang, Zhiguang Zhou	8
10	Downregulation of T-Cell Transcription Factors in Adult Latent Autoimmune Diabetes with High-Titer Glutamic Acid Decaroxylase Antibody 2019 ·Diabetes Therapy ·Xia Wang, Lin Yang, Ying Cheng, Huiying Liang, Jingping Hu, Peilin Zheng, Gan Huang, Zhiguang Zhou	3
11	PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC 2019 ·Annals of Oncology ·Yi‐Long Wu, L. Wang, Mehmet Alı Nahıt Şendur, (unknown), Zhengfei Zhu, Ying Cheng, Ping Li, Yiming Qin, Euan Macpherson, Phillip A. Dennis, Shun Lü	7
12	Clinical manifestation and islet β-cell function of a subtype of latent autoimmune diabetes in adults (LADA): positive for T cell responses in phenotypic type 2 diabetes 2019 ·Acta Diabetologica ·Huiying Liang, Ying Cheng, (unknown), (unknown), (unknown), Gan Huang, Lin Yang, Zhiguang Zhou	9
13	Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease 2018 ·Scientific Reports ·Wen Dai, Junke Long, Ying Cheng, Yaqin Chen, Shui‐Ping Zhao	28
14	A study on different therapies and prognosis-related factors for 101 patients with SCLC and brain metastases 2017 ·Cancer Biology & Therapy ·Ying Liu, Xianhong Liu, Ying Wang, Jing Zhu, Ying Xin, Kaijun Niu, Sheng Wang, Ying Cheng	7
15	Characterization of the T-cell subpopulations in the granulation tissues of chronic suppurative otitis media 2016 ·Biomedical Reports ·Bing Wang, Ying Cheng, Min Xu	4
16	Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial 2016 ·Trials ·Liang Dai, Linda L. D. Zhong, (unknown), Wei Chen, Ying Cheng, Xiufang Lin, Zhaoxiang Bian, Aiping Lü	7
17	[Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer]. 2015 ·SHILAP Revista de lepidopterología ·Shuang Zhang, Jingjing Liu, Ying Cheng	3
18	Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial breakdown → 2014 ·Journal of Clinical Oncology ·Călin Cainap, Shukui Qin, Wen‐Tsung Huang, Ik Joo Chung, Hongming Pan, Ying Cheng, Masatoshi Kudo, Yoon‐Koo Kang, Pei‐Jer Chen, (unknown), Vera Gorbunova, Ferry A.L.M. Eskens, Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, (unknown)	465
19	Hypertriglyceridemic Waist is Associated with Increased Carotid Atherosclerosis in Chronic Kidney Disease Patients 2013 ·Nephron Clinical Practice ·(unknown), (unknown), Ying Cheng, (unknown), Dan Wang, Yan Yan Wu, Xiaoyan Huang, (unknown), Tao Wang	13
20	[A pilot evaluation of the diagnostic value of body mass index in elderly men with metabolic syndrome]. 2006 ·PubMed ·Ying Cheng, Changyu Pan, Hui Tian, Juming Lu	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact